Across clinical oncology applications, from molecular testing to cancer research, the ability to identify potentially actionable genomic and genetic alterations to exploit the molecular vulnerabilities of cancer is a burgeoning field. Due to the sporadic nature of somatic cancers and the expansion of next generation sequencing, the number of variants detected through tumor testing is growing exponentially, presenting a challenge to clinical cancer genetics professionals working to confidently identify meaningful mutations that could influence decision-making at point-of-care.

 

Join Chelsea Alexander, a certified genetic counselor, and Aarthi Goverdhan, our lead oncology application development scientist, for a live webinar on Thursday, March 23rd at 11 AM EST to discover a new database that can streamline your somatic NGS analysis and significantly reduce your literature review time—by up to 90%!

 

In this webinar, we will introduce you to the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. Available as a web-based application, this expert-curated resource contains data from over 419,000 real-world clinical oncology cases combined with insights from the QIAGEN Knowledge Base, providing clinically observed variant frequencies across diseases, and diving deep into gene-level, alteration-level and disease-level information. Users can easily search and explore mutational characteristics across genes, synthesize key findings from drug labels and professional guidelines, explore clinical trials, and receive detailed annotations for each observed variant. In addition, users can interrogate a bibliography of over 170,000 PubMed articles and access detailed alteration-specific summaries written by PhD scientists.